ScholarIQanswers from OpenAlex & ORCID
Yuka Maeda
ResearcherPublications, citations & collaboration network
Yuka Maeda is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Yuka Maeda have?
ScholarIQindexed works
Yuka Maeda has 59 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Yuka Maeda have?
ScholarIQcitation count
Yuka Maeda has 12,705 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Yuka Maeda?
ScholarIQh-index
Yuka Maeda has an h-index of 24 in OpenAlex.
What is the i10-index of Yuka Maeda?
ScholarIQi10-index
Yuka Maeda has an i10-index of 30 in OpenAlex.
What is the OpenAlex record for Yuka Maeda?
ScholarIQopenalex
The OpenAlex for Yuka Maeda is on the source record.
What are the most-cited papers on Yuka Maeda?
ScholarIQmost cited works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa Ho, Martin L. Miller, Natasha Rekhtman, André L. Moreira, Fawzia K. Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher, Timothy A. Chan
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito, Hiroyoshi Nishikawa, Hisashi Wada, Yuji Nagano, Daisuke Sugiyama, Koji Atarashi, Yuka Maeda, Masahide Hamaguchi, Naganari Ohkura, Eiichi Sato, Hirotsugu Nagase, Junichi Nishimura, Hirofumi Yamamoto, Shuji Takiguchi, Takeshi Tanoue, Wataru Suda, Hidetoshi Morita, Masahira Hattori, Kenya Honda, Masaki Mori, Yuichiro� Doki, Shimon Sakaguchi
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
Shogo Kumagai, Shohei Koyama, Kota Itahashi, Tokiyoshi Tanegashima, Yi-Tzu Lin, Yosuke Togashi, Takahiro Kamada, Takuma Irie, Genki Okumura, Hidetoshi Kono, Daisuke Ito, Rika Fujii, Sho Watanabe, Atsuo Sai, Shota Fukuoka, Eri Sugiyama, Go Watanabe, Takuya Owari, Hitomi Nishinakamura, Daisuke Sugiyama, Yuka Maeda, Akihito Kawazoe, Hiroki Yukami, Keigo Chida, Yuuki Ohara, Tatsuya Yoshida, Yuki Shinno, Yuki Takeyasu, Masayuki Shirasawa, Kenta Nakama, Keiju Aokage, Jun Suzuki, Genichiro Ishii, Takeshi Kuwata, Naoya Sakamoto, Masahito Kawazu, Toshihide Ueno, Taisuke Mori, Naoya Yamazaki, Masahiro Tsuboi, Yasushi Yatabe, Takahiro Kinoshita, Toshihiko Doi, Kohei Shitara, Hiroyuki Mano, Hiroyoshi Nishikawa
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Shogo Kumagai, Yosuke Togashi, Takahiro Kamada, Eri Sugiyama, Hitomi Nishinakamura, Yoshiko Takeuchi, Vitaly Kochin, Kota Itahashi, Yuka Maeda, Shigeyuki Matsui, Takuma Shibahara, Yasuho Yamashita, Takuma Irie, Ayaka Tsuge, Shota Fukuoka, Akihito Kawazoe, Hibiki Udagawa, Keisuke Kirita, Keiju Aokage, Genichiro Ishii, Takeshi Kuwata, Kenta Nakama, Masahito Kawazu, Toshihide Ueno, Naoya Yamazaki, Kōichi Goto, Masahiro Tsuboi, Hiroyuki Mano, Toshihiko Doi, Kohei Shitara, Hiroyoshi Nishikawa
Anti-CCR4 mAb selectively depletes effector-type FoxP3 <sup>+</sup> CD4 <sup>+</sup> regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama, Hiroyoshi Nishikawa, Yuka Maeda, Megumi Nishioka, Atsushi Tanemura, Ichiro Katayama, Sachiko Ezoe, Yuzuru Kanakura, Eiichi Sato, Yasuo Fukumori, Julia Karbach, Elke Jäger, Shimon Sakaguchi